List view / Grid view
4 March 2016 | By Victoria White
Naïve pluripotent stem cells are one of the most flexible types of stem cell, which can develop into all human tissue other than the placenta...
2 March 2016 | By Victoria White
The US Patent 9,273,283 is the second patent of Celyad allogeneic intellectual property portfolio that is awarded by the USPTO...
1 March 2016 | By Merck KGaA
With EMD Millipore’s comprehensive portfolio of reagents and antibodies, researchers can count on dependable, high-quality solutions for analysing all the hallmarks of cancer...
23 February 2016 | By Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
A concise overview of some of the key features for the use of antibodies and immunochemical techniques in biological research...
18 February 2016 | By Victoria White
The results demonstrate that suppression of NR2F6 in T-cells results in increased expression of key immune stimulatory proteins IL-17 and IL-18...
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
1 February 2016 | By Victoria White
Scientists have, for the first time, identified and isolated stem cells capable of skull formation and craniofacial bone repair in mice...
27 January 2016 | By Victoria White
The study marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient's tissue...
20 January 2016 | By Victoria White
Researchers have described a novel pathway called microptosis where the immune system's killer cells deliver a 3-phase knockout punch that kills intracellular parasites...
13 January 2016 | By Oxford Global
In anticipation of our Proteins and Antibodies Congress, Bernardo Perez-Ramirez spoke to us about his research and his expectations...
12 January 2016 | By Victoria White
A new study describes the design of a CAR architecture with an integrated switch-on system that permits control over CAR T-cell functions...
6 January 2016 | By Victoria White
The Cell Therapy Catapult, the University of Birmingham and Cancer Research Technology have launched the project to develop a new immuno-oncology cellular therapy based on gene modifying T-cells to target solid tumours...
5 January 2016 | By Victoria White
AIC649 is an inactivated parapoxvirus ovis particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses...
4 January 2016 | By Victoria White
UCART19 is a potential best-in-class allogeneic Talen gene edited T-cell product for treatment of CD19 expressing haematological malignancies...
